Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,055 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection.
Nakamura Y, Aikata H, Fukuhara T, Honda F, Morio K, Morio R, Hatooka M, Kobayashi T, Nagaoki Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Kobayashi T, Ohdan H, Shiroma N, Arihiro K, Chayama K. Nakamura Y, et al. Among authors: ochi h. Hepatol Res. 2017 Jul;47(8):767-772. doi: 10.1111/hepr.12815. Epub 2016 Oct 3. Hepatol Res. 2017. PMID: 27591427
Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases.
Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Nagaoki Y, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Takahashi S, Arihiro K, Chayama K. Masaki K, et al. Among authors: ochi h. Hepatol Res. 2013 Nov;43(11):1182-9. doi: 10.1111/hepr.12094. Epub 2013 Apr 2. Hepatol Res. 2013. PMID: 23551911
Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation.
Kawaoka T, Takahashi S, Tatsukawa Y, Hiramatsu A, Hiraga N, Miki D, Tsuge M, Imamura M, Kawakami Y, Aikata H, Ochi H, Ishiyama K, Ide K, Tashiro H, Ohdan H, Chayama K. Kawaoka T, et al. Among authors: ochi h. Hepatol Res. 2014 Nov;44(12):1259-64. doi: 10.1111/hepr.12296. Epub 2014 Feb 17. Hepatol Res. 2014. PMID: 24382214
Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease.
Kan H, Kimura Y, Hyogo H, Fukuhara T, Fujino H, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Ochi H, Arihiro K, Chayama K. Kan H, et al. Among authors: ochi h. Hepatol Res. 2014 Dec;44(14):E420-7. doi: 10.1111/hepr.12330. Epub 2014 Apr 15. Hepatol Res. 2014. PMID: 24636073
Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C.
Nagaoki Y, Imamura M, Kawakami Y, Kan H, Fujino H, Fukuhara T, Kobayashi T, Ono A, Nakahara T, Naeshiro N, Urabe A, Yokoyama S, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiramatsu A, Aikata H, Takahashi S, Hayes CN, Ochi H, Chayama K; Hiroshima Liver Study Group. Nagaoki Y, et al. Among authors: ochi h. Hepatol Res. 2014 Dec;44(14):E447-54. doi: 10.1111/hepr.12336. Epub 2014 May 6. Hepatol Res. 2014. PMID: 24690180
Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis.
Naeshiro N, Aikata H, Hyogo H, Kan H, Fujino H, Kobayashi T, Fukuhara T, Honda Y, Nakahara T, Ohno A, Miyaki D, Murakami E, Kawaoka T, Tsuge M, Hiraga N, Hiramatsu A, Imamura M, Kawakami Y, Ochi H, Chayama K. Naeshiro N, et al. Among authors: ochi h. Hepatol Res. 2015 Jun;45(6):656-62. doi: 10.1111/hepr.12400. Epub 2014 Sep 2. Hepatol Res. 2015. PMID: 25088236
Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus.
Kan H, Hyogo H, Ochi H, Hotta K, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Chayama K. Kan H, et al. Among authors: ochi h. Hepatol Res. 2016 Mar;46(3):E146-53. doi: 10.1111/hepr.12552. Epub 2015 Jul 29. Hepatol Res. 2016. PMID: 26147768
Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study.
Nagaoki Y, Aikata H, Nakano N, Shinohara F, Nakamura Y, Hatooka M, Morio K, Kan H, Fujino H, Kobayashi T, Fukuhara T, Masaki K, Ono A, Nakahara T, Kawaoka T, Miki D, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Kawakami Y, Ochi H, Chayama K; Hiroshima Liver Study Group. Nagaoki Y, et al. Among authors: ochi h. J Gastroenterol Hepatol. 2016 May;31(5):1009-15. doi: 10.1111/jgh.13236. J Gastroenterol Hepatol. 2016. PMID: 26584407
Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report.
Tsuge M, Hiramatsu A, Shinohara F, Nakano N, Nakamura Y, Hatooka M, Morio K, Morio R, Kan H, Fujino H, Uchida T, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Ono A, Nagaoki Y, Miki D, Kawaoka T, Hiraga N, Imamura M, Kawakami Y, Aikata H, Ochi H, Nelson Hayes C, Chayama K. Tsuge M, et al. Among authors: ochi h. Hepatol Res. 2016 Aug;46(9):944-8. doi: 10.1111/hepr.12629. Epub 2016 Jan 30. Hepatol Res. 2016. PMID: 26613201
1,055 results